X4 Pharmaceuticals (XFOR) Profit After Tax (2017 - 2025)

X4 Pharmaceuticals has reported Profit After Tax for 9 years, with the latest figure at -$23.9 million in Q4 2025.

• For the quarter ending Q4 2025, Profit After Tax rose 39.92% year-over-year to -$23.9 million; the trailing twelve-month figure through Dec 2025 stood at -$79.2 million (down 111.48% YoY), and the FY2025 full-year result was -$79.2 million, down 111.48% from the prior year.
• Profit After Tax for Q4 2025 stood at -$23.9 million, up from -$29.8 million in the prior quarter.
• The five-year high for Profit After Tax was $90.8 million in Q2 2024, with the low at -$55.7 million in Q2 2023.
• Historically, Profit After Tax has averaged -$20.0 million across 5 years, with a median of -$22.9 million in 2022.
• The largest YoY upside for Profit After Tax was 263.04% in 2024 against a maximum downside of 1492.02% in 2024.
• X4 Pharmaceuticals' Profit After Tax stood at -$30.2 million in 2021, then climbed by 3.65% to -$29.1 million in 2022, then surged by 34.27% to -$19.1 million in 2023, then sank by 108.16% to -$39.8 million in 2024, then surged by 39.92% to -$23.9 million in 2025.
• The last three Profit After Tax figures came in at -$23.9 million (Q4 2025), -$29.8 million (Q3 2025), and -$25.7 million (Q2 2025), per Business Quant data.